Kombiglyze XR approved for treatment of type 2 diabetes mellitus (DM)

Kombiglyze XR available for type 2 diabetes

Bristol-Myers Squibb and AstraZeneca announced that Kombiglyze XR (saxagliptin and metformin HCl extended-release) is now available for the treatment of type 2 diabetes as an adjunct to diet and exercise when treatment with both saxagliptin and metformin is appropriate.

Supplemental NDA submitted for Byetta for add-on therapy to insulin

Amylin Pharmaceuticals and Eli Lily announced that a supplemental New Drug Application (sNDA) has been submitted to the FDA for the expanded use of Byetta (exenatide) injection as an add-on therapy to basal insulin, with or without metformin and/or a thiazolidinedione (TZD) in conjunction with diet and exercise for adults with type 2 diabetes who are not achieving adequate glycemic control.